Skip to main content

Dermatology

CBT or Naltrexone in Fibromyalgia (12.8.2023)

Dec 08, 2023

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  Be sure to catch the early registration break for 2024 RheumNow Live




  1. Palmoplantar pustulosis (PPP) is difficult to treat; w/ few reports of JAKi efficacy. Now

Read Article
#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest https://t.co/Rj1k1z0Tsz
Rashes in Rheumatology at #ACR23 Name the rash? @Rheumnow https://t.co/7CNqOESctW

Pregnancy Updates That Will Change The Way I Practice

Nov 12, 2023

ACR Convergence is truly drinking from the proverbial fire hose. It’s a beautiful mash-up of basic science and treatment updates meets guidelines, recommendations, and disease identification. My goal when attending any conference is to learn as much as I can, synthesize that information, and

Read Article

ACR Convergence Preview (11.10.2023)

Nov 10, 2023

Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting. 




  1. 2023 Medscaped Female Compensation Survey asked What percentage would again chose their specialty ? Top 5

Read Article
FDA has approved another ustekinumab biosimilar (Wezlana) as being interchangeable for use in adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. https://t.co/zbQKjmKgZh https://t.co/UuTDRgCBIV

Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitor Treatment of Skin Disorders

Nov 01, 2023

A JAMA systematic review and meta-analysis has showed the use of JAK inhibitors (JAKi) in immune-mediated inflammatory skin diseases was not associated with increased risk of all-cause mortality, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE) (compared to the

Read Article
JAKne? Systematic review &meta-analysis (25 studies, 10 839 pts), JAK inhibitor use was associated with an elevated odds of acne (OR 3-5 for UPA, TOFA, BARI, Deucra; but higher for abrocitinib (OR 13.5). Seen in Derm pts but hardly at all in Rheum pts https://t.co/En8HCqwqjO https://t.co/ak216wmlBA
Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaque Psoriasis https://t.co/Eo4LMaTHxn https://t.co/abzlThasEN

Methotrexate in OA (10.20.2023)

Oct 20, 2023

Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.

Read Article

2023 EULAR Lupus Management Recommendations

Oct 17, 2023

EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations.



A multinational international Task Force included  35 rheumatologists, five

Read Article

Sleep Apnea Smart Watches (10.13.2023)

Oct 13, 2023

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.




  1. Full Read review of #PMR in Lancet: - Start @ 12·5–25mg prednisone qd - Remission in most but, relapses in 40–60% - Onset sudden; AM stiffness predominates;

Read Article

Microvascular CV Disease with Severe Psoriasis

Sep 26, 2023

While comorbidities, including an increased cardiovascular (CV) risk, are associated with severe psoriasis, less is known about subclinical CV disease and when it occurs in patients with psoriasis. 



Coronary microvascular dysfunction (CMD) has been shown to be predictive of future

Read Article

RheumNow Podcast with Special Guest Dr. Michael Weinblatt (9.22.2023)

Sep 22, 2023

Dr. Jack Cush is joined by Dr. Michael Weinblatt as they discuss this weeks news and journal reports, including difficult RA, HLA typing and abatacept responses and new regulatory decisions. 




  1. UCB has issued a press update on its pending application for the approval of their

Read Article

Hard Decisions in RA (9.1.2023)

Sep 01, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article

Manifestations of Systemic Sclerosis Sine Scleroderma

Aug 21, 2023

Systemic sclerosis (SSc) sine scleroderma is a unique and rare subset of SSc defined by the absence of skin fibrosis. An analysis of the EUSTAR database suggests systemic disease can be a problem, including interstitial lung disease (>40%) and SSc renal crisis (almost 3%). 

Read Article

Mono- and Oligo- are Different (8.18.2023)

Aug 18, 2023

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.




  1. Glucocorticoid Affects Weight, but not Blood Pressure in RA A pooled analysis of 5 RCTs shows that the effects of 2 years of low-dose glucocorticoid (GC) treatment in RA can significantly

Read Article

Pizza and Rheumatoid Arthritis (8.11.2023)

Aug 11, 2023

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:




  1. Swedish study of 325 #AAV pts saw CVA in 35 pts (8%); CVA incidence=11.3/1000 PYs - this was higher than gen population [SIR 1.85). AAV CVA risk factors included age

Read Article

PRESTO Tool Predicts the Risk of Psoriatic Arthritis

EurekAlert!
Aug 09, 2023

In research published in Arthritis & Rheumatology, investigators developed and validated a tool called PRESTO that

Read Article
IMMpulse study - 1 yr OL, phase 4 trial of risankizumab (150 mg, wk 0, 4) vs apremilast (30 mg bid) in 352 pts w/ moderate plaque psoriasis. RIZ had superior efficacy at wk 16 w/ PASI90 score of 55.9% vs 5.1% for APR. https://t.co/dSLJA9Tsmx https://t.co/AHPHdmOtM3

IL-23 Inhibitor Performance in Psoriatic Disease

Jul 27, 2023

IL-23 inhibitors are approved for the treatment of psoriasis and psoriatic arthritis; a single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA.

Read Article
Link Between Vitamin D and Psoriasis Severity More than 8M people in the US experience psoriasis-a person’s vitamin D levels could play an important role in psoriasis severity, according to one of the largest studies to date. https://t.co/IMvFS0Vp4v https://t.co/cmQAIQ0U4p

Link Between Vitamin D and Psoriasis Severity

EurekAlert!
Jul 25, 2023

More than eight million people in the U.S. experience psoriasis, a condition in which skin cells build up and form itchy dry patches. A person’s vitamin D levels could play an important role in psoriasis severity, according to one of the largest studies to date.



The analysis, which

Read Article
EULAR Points to Consider in Progressing Psoriasis to Psoriatic Arthritis The transition from psoriasis to PsA – and the early diagnosis of PsA – is of considerable scientific and clinical interest. https://t.co/KYLBU3E0k6 https://t.co/oHgqEX8Gr6

EULAR Points to Consider in Progressing Psoriasis to Psoriatic Arthritis

Jul 17, 2023

The transition from psoriasis to PsA – and the early diagnosis of PsA – is of considerable scientific and clinical interest. People typically have psoriatic skin disease for a decade or more before they begin to experience the joint involvement of PsA. Understanding more about the natural

Read Article
×